CombiMatrix's Array for Pre-Implantation Genetic Screening Granted Conditional Approval From New York State Department of Health

CombiMatrix Corporation CBMX today announced that its CombiPGS™ test for women undergoing in vitro fertilization (IVF) has received conditional approval from the New York State Department of Health. CombiPGS allows couples to screen embryo biopsy cells for chromosomal abnormalities prior to implantation of the embryo in order to maximize the chance of successful implantation and pregnancy progression and to decrease the likelihood of a miscarriage. "The demand for our CombiPGS test across the country has been strong since our launch in early 2015. We are very excited to now offer this service in New York State, which ranks second only to California in the total number of IVF cycles performed nationally each year," said Mark McDonough, President and Chief Executive Officer of CombiMatrix. "California has been our top producing state for the adoption of CombiPGS and we are optimistic that we can replicate that success in New York. It is worth noting that CombiMatrix is the first national commercial diagnostic laboratory to offer PGS testing with per-embryo pricing, allowing See full press release
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsOfferingsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!